Pauline Duconseil

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Marine Gilabert · 9 shared papers, 2015–2021 · strength 0.52
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
2. Marc F. Giovannini · 8 shared papers, 2015–2021 · strength 0.47
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
3. Odile Gayet · 8 shared papers, 2015–2021 · strength 0.43
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
   • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
4. Juan Iovanna · 8 shared papers, 2015–2021 · strength 0.43
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
   • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
5. Nelson Dusetti · 8 shared papers, 2015–2021 · strength 0.43
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
   • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
6. Olivıer Turrini · 8 shared papers, 2015–2019 · strength 0.40
   • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
   • Paper Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two differ… DOI 10.1016/j.ejso.2017.06.011↗
   • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
7. Jean‐Robert Delpéro · 5 shared papers, 2016–2019 · strength 0.29
   • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
   • Paper Resectable invasive IPMN versus sporadic pancreatic adenocarcinoma of the head of the pancreas: Should these two differ… DOI 10.1016/j.ejso.2017.06.011↗
   • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
8. Rémy Nicolle · 4 shared papers, 2017–2021 · strength 0.27
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
   • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
9. Julie Roques · 3 shared papers, 2017–2021 · strength 0.21
   • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
   • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
   • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
10. Véronique Secq · 5 shared papers, 2015–2018 · strength 0.21
    • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
11. Céline Loncle · 5 shared papers, 2015–2017 · strength 0.20
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
    • Paper Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarci… DOI 10.18632/oncotarget.3510↗
12. Mehdi Ouaïssi · 5 shared papers, 2015–2017 · strength 0.20
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
    • Paper Deciphering the cellular source of tumor relapse identifies CD44 as a major therapeutic target in pancreatic adenocarci… DOI 10.18632/oncotarget.3510↗
13. Jonathan Garnier · 3 shared papers, 2016–2019 · strength 0.17
    • Paper Effect of clinical status on survival in patients with borderline or locally advanced pancreatic adenocarcinoma. DOI 10.1186/s12957-019-1637-1↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
14. Jerome F. Cros · 2 shared papers, 2020–2021 · strength 0.17
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
    • Paper Establishment of a pancreatic adenocarcinoma molecular gradient (PAMG) that predicts the clinical outcome of pancreatic… DOI 10.1016/j.ebiom.2020.102858↗
15. Benjamin Bian · 3 shared papers, 2016–2018 · strength 0.14
    • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper A pancreatic ductal adenocarcinoma subpopulation is sensitive to FK866, an inhibitor of NAMPT. DOI 10.18632/oncotarget.10776↗
16. Jean‐Luc Raoul · 3 shared papers, 2015–2017 · strength 0.12
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
    • Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
17. Anthony Gonçalvès · 3 shared papers, 2015–2017 · strength 0.12
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
    • Paper Transcriptomic analysis predicts survival and sensitivity to anticancer drugs of patients with a pancreatic adenocarcin… DOI 10.1016/j.ajpath.2014.11.029↗
    • Paper A subgroup of pancreatic adenocarcinoma is sensitive to the 5-aza-dC DNA methyltransferase inhibitor. DOI 10.18632/oncotarget.2685↗
18. Raul A. Urrutia · 2 shared papers, 2017–2018 · strength 0.10
    • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
19. Gwen Alyce Lomberk · 2 shared papers, 2017–2018 · strength 0.10
    • Paper Distinct epigenetic landscapes underlie the pathobiology of pancreatic cancer subtypes. DOI 10.1038/s41467-018-04383-6↗
    • Paper Pancreatic Adenocarcinoma Therapeutic Targets Revealed by Tumor-Stroma Cross-Talk Analyses in Patient-Derived Xenograft… DOI 10.1016/j.celrep.2017.11.003↗
20. Laëtitia Dahan · 1 shared paper, 2021 · strength 0.09
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
21. Magali Svrcek · 1 shared paper, 2021 · strength 0.09
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
22. Jean‐Luc Van Laethem · 1 shared paper, 2021 · strength 0.09
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
23. Francesco Puleo · 1 shared paper, 2021 · strength 0.09
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
24. Pascal R. Hammel · 1 shared paper, 2021 · strength 0.09
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗
25. Jean‐Baptiste Bachet · 1 shared paper, 2021 · strength 0.09
    • Paper A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. DOI 10.1016/j.annonc.2020.10.601↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.